Literature DB >> 26613734

Interactions between imidazoline I2 receptor ligands and acetaminophen in adult male rats: antinociception and schedule-controlled responding.

Justin N Siemian1, Jiuzhou Li2, Yanan Zhang3, Jun-Xu Li4.   

Abstract

RATIONALE: Recent evidence suggests that imidazoline I2 receptor ligands are suitable for combination therapy with opioids. Quantitative analysis of I2 receptor ligands combined with non-opioid drugs is necessary for the justification of alternative pain therapies.
OBJECTIVE: This study systematically examined the antihyperalgesic and response rate-suppressing effects of selective I2 receptor ligands (2-BFI and phenyzoline) alone and in combination with acetaminophen.
METHODS: Von Frey and Hargreaves tests were used to examine the antihyperalgesic effects of drugs in complete Freund's adjuvant (CFA)-induced inflammatory pain in rats. Food-reinforced schedule-controlled responding was used to assess the rate-suppressing effects of study drugs. Dose-addition and isobolographic analyses were used to assess drug-drug interactions for all assays.
RESULTS: 2-BFI (3.2-17.8 mg/kg, i.p.), phenyzoline (17.8-100 mg/kg, i.p.), and acetaminophen (56-178 mg/kg, i.p.) all dose-dependently produced significant antinociceptive effects. When studied as combinations, 2-BFI and acetaminophen produced infra-additive to additive interactions while phenyzoline and acetaminophen produced additive to supra-additive interactions. The same drug combinations suppressed response rate in a supra-additive manner.
CONCLUSIONS: Quantitative analysis of the antihyperalgesic and response rate-suppressing effects suggests that I2 receptor ligands are not well suited to combination therapy with acetaminophen.

Entities:  

Keywords:  Acetaminophen; Antinociception; Complete Freund’s adjuvant; Dose-addition analysis; Imidazoline I2 receptor; Rats

Mesh:

Substances:

Year:  2015        PMID: 26613734      PMCID: PMC4752914          DOI: 10.1007/s00213-015-4166-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  30 in total

1.  Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010.

Authors:  Matthew Daubresse; Hsien-Yen Chang; Yuping Yu; Shilpa Viswanathan; Nilay D Shah; Randall S Stafford; Stefan P Kruszewski; G Caleb Alexander
Journal:  Med Care       Date:  2013-10       Impact factor: 2.983

2.  Increased tumor necrosis factor-alpha and prostaglandin E2 concentrations in the cerebrospinal fluid of rats with inflammatory hyperalgesia: the effects of analgesic drugs.

Authors:  Mauro Bianchi; Cataldo Martucci; Paolo Ferrario; Silvia Franchi; Paola Sacerdote
Journal:  Anesth Analg       Date:  2007-04       Impact factor: 5.108

3.  Effects of serotonin (5-HT)1A and 5-HT2A receptor agonists on schedule-controlled responding in rats: drug combination studies.

Authors:  Jun-Xu Li; Caroline Crocker; Wouter Koek; Kenner C Rice; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2010-12-21       Impact factor: 4.530

4.  Acetaminophen reduces lipopolysaccharide-induced fever by inhibiting cyclooxygenase-2.

Authors:  Linda Engström Ruud; Daniel Björk Wilhelms; Anna Eskilsson; Ana Maria Vasilache; Louise Elander; David Engblom; Anders Blomqvist
Journal:  Neuropharmacology       Date:  2013-03-29       Impact factor: 5.250

Review 5.  Imidazoline I2 receptors: target for new analgesics?

Authors:  Jun-Xu Li; Yanan Zhang
Journal:  Eur J Pharmacol       Date:  2011-03-01       Impact factor: 4.432

6.  Brain protection conferred by long-term administration of 2-(2-benzofuranyl)-2-imidazoline against experimental autoimmune encephalomyelitis.

Authors:  Ying-Biao Zhu; Nian-Ge Xia; Yuan-Tao Zhang; Xin-Shi Wang; Shan-Shan Liang; Wei-Yong Yin; Hui-Qin Xu; Sheng-Tao Hou; Rong-Yuan Zheng
Journal:  Neurochem Res       Date:  2014-12-19       Impact factor: 3.996

Review 7.  Pharmacologic characterization of imidazoline receptor proteins identified by immunologic techniques and other methods.

Authors:  P V Escribá; A Ozaita; J A García-Sevilla
Journal:  Ann N Y Acad Sci       Date:  1999-06-21       Impact factor: 5.691

Review 8.  Nonopioid medications for pain.

Authors:  David Tauben
Journal:  Phys Med Rehabil Clin N Am       Date:  2015-05       Impact factor: 1.784

9.  2-BFI ameliorates EAE-induced mouse spinal cord damage: effective therapeutic time window and possible mechanisms.

Authors:  Fang Li; Zheng-Xue Zhang; Yin-Feng Liu; Hui-Qin Xu; Sheng-Tao Hou; Rong-Yuan Zheng
Journal:  Brain Res       Date:  2012-09-14       Impact factor: 3.252

10.  Evaluation of analgesic efficacy, gastrotoxicity and nephrotoxicity of fixed-dose combinations of nonselective, preferential and selective cyclooxygenase inhibitors with paracetamol in rats.

Authors:  Gaurav Kumar; Debasish Hota; Uma Nahar Saikia; Promila Pandhi
Journal:  Exp Toxicol Pathol       Date:  2009-10-02
View more
  5 in total

1.  Tolerance and cross-tolerance to the antinociceptive effects of oxycodone and the imidazoline I2 receptor agonist phenyzoline in adult male rats.

Authors:  David A Thorn; Yanan Zhang; Jun-Xu Li
Journal:  Psychopharmacology (Berl)       Date:  2017-03-17       Impact factor: 4.530

2.  Role of intracellular Ca2+ signaling in the antinociceptive and discriminative stimulus effects of the imidazoline I2 receptor agonist 2-BFI in rats.

Authors:  Justin N Siemian; Yanyan Qiu; Yanan Zhang; Jun-Xu Li
Journal:  Psychopharmacology (Berl)       Date:  2017-08-19       Impact factor: 4.530

Review 3.  Imidazoline I2 receptors: An update.

Authors:  Jun-Xu Li
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

Review 4.  Application of dose-addition analyses to characterize the abuse-related effects of drug mixtures.

Authors:  Michelle R Doyle; Brenda M Gannon; Melson P Mesmin; Gregory T Collins
Journal:  J Exp Anal Behav       Date:  2022-02-10       Impact factor: 2.215

Review 5.  Systematic Review of Systemic and Neuraxial Effects of Acetaminophen in Preclinical Models of Nociceptive Processing.

Authors:  Hiroshi Hoshijima; Matthew Hunt; Hiroshi Nagasaka; Tony Yaksh
Journal:  J Pain Res       Date:  2021-11-12       Impact factor: 3.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.